S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:BIOL

BIOLASE - BIOL Stock Forecast, Price & News

$5.45
-0.04 (-0.73%)
(As of 08/9/2022 05:12 PM ET)
Add
Compare
Today's Range
$5.04
$5.48
50-Day Range
$4.10
$5.49
52-Week Range
$3.30
$23.49
Volume
47,434 shs
Average Volume
53,211 shs
Market Capitalization
$33.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.50

BIOLASE MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
661.5% Upside
$41.50 Price Target
Short Interest
Healthy
3.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.01mentions of BIOLASE in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

768th out of 1,098 stocks

Dental Equipment & Supplies Industry

4th out of 6 stocks

BIOL stock logo

About BIOLASE (NASDAQ:BIOL) Stock

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Analysts Set New Price Targets

BIOL has been the subject of several recent research reports. Lake Street Capital initiated coverage on shares of BIOLASE in a research report on Friday, May 20th. They issued a "buy" rating and a $12.00 price objective for the company. StockNews.com initiated coverage on shares of BIOLASE in a research report on Friday. They issued a "sell" rating for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, BIOLASE currently has an average rating of "Moderate Buy" and an average price target of $41.50.

BIOLASE Stock Performance

BIOL traded down $0.44 during trading hours on Tuesday, reaching $5.05. 36 shares of the stock traded hands, compared to its average volume of 29,712. The firm's fifty day simple moving average is $4.52 and its two-hundred day simple moving average is $7.34. BIOLASE has a fifty-two week low of $3.30 and a fifty-two week high of $23.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.34 and a quick ratio of 2.22.

BIOLASE (NASDAQ:BIOL - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The medical technology company reported ($0.81) earnings per share for the quarter. BIOLASE had a negative net margin of 34.03% and a negative return on equity of 62.40%. The firm had revenue of $10.17 million for the quarter.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Stock News Headlines

BIOLASE (BIOL) Scheduled to Post Quarterly Earnings on Thursday
StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)
BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com
BIOLASE ANNOUNCES PROMOTIONS OF KEY TEAM MEMBERS
BIOLASE ANNOUNCES ADVANCING DENTISTRY PODCAST
See More Headlines
Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Dental equipment & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.50
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+661.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-16,160,000.00
Pretax Margin
-33.98%

Debt

Sales & Book Value

Annual Sales
$39.19 million
Book Value
$4.11 per share

Miscellaneous

Free Float
6,046,000
Market Cap
$33.66 million
Optionable
Not Optionable
Beta
1.48














BIOL Stock - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings
or view top-rated stocks.

What is BIOLASE's stock price forecast for 2022?

4 Wall Street analysts have issued 12-month price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $12.00 to $75.00. On average, they anticipate the company's stock price to reach $41.50 in the next twelve months. This suggests a possible upside of 693.5% from the stock's current price.
View analysts price targets for BIOL
or view top-rated stocks among Wall Street analysts.

How has BIOLASE's stock price performed in 2022?

BIOLASE's stock was trading at $9.75 at the beginning of 2022. Since then, BIOL stock has decreased by 46.4% and is now trading at $5.23.
View the best growth stocks for 2022 here
.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our BIOL earnings forecast
.

How can I listen to BIOLASE's earnings call?

BIOLASE will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "46222".

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) issued its earnings results on Thursday, May, 12th. The medical technology company reported ($0.81) earnings per share for the quarter. The medical technology company earned $10.17 million during the quarter. BIOLASE had a negative net margin of 34.03% and a negative trailing twelve-month return on equity of 62.40%.

When did BIOLASE's stock split?

Shares of BIOLASE reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE issued an update on its second quarter 2022 earnings guidance on Thursday, June, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.50M-, compared to the consensus revenue estimate of $10.20 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (1.92%) and Capital Wealth Alliance LLC (1.10%). Insiders that own company stock include Jack W Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends
.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $5.23.

How much money does BIOLASE make?

BIOLASE (NASDAQ:BIOL) has a market capitalization of $32.32 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does BIOLASE have?

BIOLASE employs 158 workers across the globe.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.

This page (NASDAQ:BIOL) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.